These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27138868)

  • 1. Confirmation of Biosimilarity in a Pharmacokinetic/Pharmacodynamic Study in Healthy Volunteers for an Analytically Highly Similar Pegfilgrastim.
    Desai K; Catalano T; Rai G; Misra P; Shah N
    Clin Pharmacol Drug Dev; 2016 Sep; 5(5):354-63. PubMed ID: 27138868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects.
    Nakov R; Gattu S; Wang J; Velinova M; Schaffar G; Skerjanec A
    Br J Clin Pharmacol; 2018 Dec; 84(12):2790-2801. PubMed ID: 30079636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim.
    Waller CF; Tiessen RG; Lawrence TE; Shaw A; Liu MS; Sharma R; Baczkowski M; Kothekar MA; Micales CE; Barve A; Ranganna GM; Pennella EJ
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1087-1095. PubMed ID: 29671069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg
    Roth K; Lehnick D; Wessels H; Höfler J; Gastl B; Jankowsky R
    Pharmacol Res Perspect; 2019 Oct; 7(5):e00503. PubMed ID: 31417680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics, safety, and immunogenicity of Pelmeg
    Wessels H; Lehnick D; Höfler J; Jankowsky R; Chamberlain P; Roth K
    Pharmacol Res Perspect; 2019 Oct; 7(5):e00507. PubMed ID: 31417681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic bioequivalence study of a pegfilgrastim biosimilar INTP5 in healthy subjects.
    Singh I; Patel A; Patel R; Jose V
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):329-337. PubMed ID: 29948023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
    Blackwell K; Donskih R; Jones CM; Nixon A; Vidal MJ; Nakov R; Singh P; Schaffar G; Gascón P; Harbeck N
    Oncologist; 2016 Jul; 21(7):789-94. PubMed ID: 27091420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized, Open-Label Study Conducted to Evaluate the Bioequivalence of Pegfilgrastim-cbqv On-Body Injector Versus Prefilled Syringe in Healthy Male Participants.
    Tang H; Civoli F; Tatarewicz S; Vandenkoornhuyse N; Finck B
    Adv Ther; 2024 Mar; 41(3):991-1009. PubMed ID: 38180721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Biosimilarity of ior
    Licollari A; Riddle K; Taylor SR; Ledon N; Bolger GT
    J Pharm Sci; 2017 Jun; 106(6):1475-1481. PubMed ID: 28238900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia.
    Melhem M; Delor I; Pérez-Ruixo JJ; Harrold J; Chow A; Wu L; Jacqmin P
    Br J Clin Pharmacol; 2018 May; 84(5):911-925. PubMed ID: 29318653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy.
    Desai K; Misra P; Kher S; Shah N
    Exp Hematol Oncol; 2018; 7():22. PubMed ID: 30202638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First Pegfilgrastim Biosimilar Approved.
    Aschenbrenner DS
    Am J Nurs; 2018 Oct; 118(10):19-20. PubMed ID: 30260881
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer.
    Yao HM; Jones SR; Morales S; Moosavi S; Zhang J; Freyman A; Ottery FD
    Cancer Chemother Pharmacol; 2021 Dec; 88(6):1033-1048. PubMed ID: 34618197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients.
    Botteri E; Krendyukov A; Curigliano G
    Eur J Cancer; 2018 Jan; 89():49-55. PubMed ID: 29227817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A demonstration of analytical similarity comparing a proposed biosimilar pegfilgrastim and reference pegfilgrastim.
    Brokx S; Scrocchi L; Shah N; Dowd J
    Biologicals; 2017 Jul; 48():28-38. PubMed ID: 28619479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers.
    Choi C; Yoo BW; Kim CO; Hong T; Jin BH; Seo KS; Jang JY; Park MS
    Drug Des Devel Ther; 2018; 12():2381-2387. PubMed ID: 30122896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.
    McBride A; Campbell K; Bikkina M; MacDonald K; Abraham I; Balu S
    J Med Econ; 2017 Oct; 20(10):1083-1093. PubMed ID: 28722494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
    Blackwell K; Gascon P; Jones CM; Nixon A; Krendyukov A; Nakov R; Li Y; Harbeck N
    Ann Oncol; 2017 Sep; 28(9):2272-2277. PubMed ID: 28637287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics.
    Sörgel F; Schwebig A; Holzmann J; Prasch S; Singh P; Kinzig M
    BioDrugs; 2015 Apr; 29(2):123-31. PubMed ID: 25837839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim.
    Brekkan A; Lopez-Lazaro L; Yngman G; Plan EL; Acharya C; Hooker AC; Kankanwadi S; Karlsson MO
    AAPS J; 2018 Aug; 20(5):91. PubMed ID: 30112626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.